Protara Therapeutics (TARA) Set to Announce Earnings on Monday

Protara Therapeutics (NASDAQ:TARA) is projected to announce its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Protara Therapeutics to post earnings of ($0.3657) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). On average, analysts expect Protara Therapeutics to post ($1.40) EPS for the current fiscal year and ($1.69) EPS for the next fiscal year.

Protara Therapeutics Price Performance

TARA stock opened at $2.48 on Monday. The business has a 50 day moving average of $3.19 and a 200 day moving average of $4.56. The firm has a market cap of $146.57 million, a PE ratio of -1.84 and a beta of 1.54. Protara Therapeutics has a twelve month low of $2.28 and a twelve month high of $7.82.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TARA. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $26.25.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.

Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.